Rahimzadeh Golnar, Rezai Shaghayegh, Abbasi Ghazal, Soleimanpour Saman, Valadan Reza, Vahedi Laleh, Sheidaei Somayeh, Movahedi Faezeh Sadat, Rezai Raha, Rezai Mohammad Sadegh
Pediatric Infectious Diseases Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Department of Medical Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Iran J Microbiol. 2024 Dec;16(6):745-754. doi: 10.18502/ijm.v16i6.17247.
is a common pathogen associated with healthcare-related infections. It is particularly notable for its ability to develop resistance to multiple antibiotics, making treatment challenging. During the COVID-19 pandemic, increased antibiotic use to manage critically ill patients was contributed to the rise of multidrug-resistant . This study evaluated the antibiotic resistance patterns of multidrug-resistant, ESBL-producing in northern Iran after the COVID-19 pandemic.
This cross-sectional study was conducted between September 2022 and October 2023. Clinical samples were collected from patients with nosocomial infections at hospitals in Sari. This study included 114 multidrug-resistant ESBLs-producing isolates. Antimicrobial susceptibility was assessed using broth macro-dilution, and resistance genes were detected by multiplex PCR.
Gentamicin, ampicillin-sulbactam, co-amoxiclav, and ceftazidime displayed the lowest activity against multi-drug-resistant . In contrast, piperacillin-tazobactam showed the highest activity. The prevalence of resistance genes was as follows: (99.12%), (74.56%), (88.60%), (64.04%), (92.98%), and (67.54%).
This study identified over 50% of antibiotic-resistance genes. Over half of multidrug-resistant isolates showed resistance to antibiotics except piperacillin-tazobactam, which is recommended for treating multi-drug-resistant infections.
是一种与医疗相关感染有关的常见病原体。其特别值得注意的是能够对多种抗生素产生耐药性，这使得治疗具有挑战性。在新冠疫情期间，用于治疗重症患者的抗生素使用增加导致了多重耐药菌的增多。本研究评估了新冠疫情后伊朗北部多重耐药、产超广谱β-内酰胺酶（ESBL）的抗生素耐药模式。
本横断面研究于2022年9月至2023年10月进行。从萨里市医院的医院感染患者中收集临床样本。本研究纳入了114株产ESBL的多重耐药菌分离株。采用肉汤宏观稀释法评估抗菌药物敏感性，并通过多重聚合酶链反应检测耐药基因。
庆大霉素、氨苄西林-舒巴坦、阿莫西林-克拉维酸和头孢他啶对多重耐药菌的活性最低。相比之下，哌拉西林-他唑巴坦的活性最高。耐药基因的流行率如下：（99.12%）、（74.56%）、（88.60%）、（64.04%）、（92.98%）和（67.54%）。
本研究鉴定出超过50%的抗生素耐药基因。超过一半的多重耐药菌分离株对除哌拉西林-他唑巴坦以外的抗生素耐药，推荐使用哌拉西林-他唑巴坦治疗多重耐药菌感染。
